In re: Diet Drugs v.

CourtCourt of Appeals for the Third Circuit
DecidedJanuary 21, 2020
Docket19-2195
StatusUnpublished

This text of In re: Diet Drugs v. (In re: Diet Drugs v.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: Diet Drugs v., (3d Cir. 2020).

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________

No. 19-2195 _____________

IN RE: DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE) PRODUCTS LIABILITY LITIGATION

NORMA SCHLAGER, Appellant _______________________________________

On Appeal from the United States District Court for the Eastern District of Pennsylvania (No. 2-99-cv-20593; 2-11-md-01203; 2-15-md-01203) District Judge: Honorable Harvey Bartle, III _______________________________________

Submitted Pursuant to Third Circuit L.A.R. 34.1(a) January 16, 2020

Before: HARDIMAN, PORTER, and PHIPPS, Circuit Judges.

(Opinion filed: January 21, 2020)

____________

OPINION* ____________

* This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent. PHIPPS, Circuit Judge.

This appeal addresses the timeliness of a claim for benefits under a nationwide

class action settlement related to the ingestion of diet drugs and the onset of valvular

heart disease. The terms of the settlement agreement provided for two damage matrices:

a low-level matrix and a high-level matrix. Norma Schlager is a class member who

initially sought low-level matrix benefits. She now seeks high-level matrix benefits due

to valvular heart surgery she underwent on September 2, 2010, and a stroke she had on

June 29, 2014.

Due to the terms of the settlement agreement and her lack of an opt-out,

Schlager’s ability to recover high-level matrix benefits is governed by the Seventh

Amendment to the settlement agreement. Under that provision, to seek high-level matrix

benefits after initially requesting low-level matrix benefits, a class member must meet

certain requirements. For Schlager, who last ingested diet drugs in 1995, she needed to

experience a qualifying event triggering a claim for benefits (a) no later than

December 31, 2011, and (b) while she was 79 years old or under. And to request high-

level matrix benefits, she needed to submit a document, referred to as the Green Form, to

the administrator of the settlement trust. The Green Form had to be completed either by

her or her representative, and a physician.

Originally, the Seventh Amendment did not include a time period for submitting a

Green Form. But an order entered by the District Court, referred to as ‘Court Approved

Procedure 16,’ imposed deadlines for the Green Form. That order dictated that a

completed Green Form must have been received within four years after the later of (i) the

2 date of the order, which was entered on November 8, 2010, or (ii) the first diagnosis of

“the last occurring condition or event upon which the claim for [high-level matrix

benefits] is based.” Court Approved Procedure No. 16 at 2, In re Diet Drugs

(Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig., 2:11-md-01203

(E.D. Pa. Nov. 5, 2001).

Here, Schlager seeks Level IV high-level matrix benefits based on her 2010

surgery and her 2014 stroke. To obtain those benefits, Schlager completed and submitted

a Green Form, which was received on February 6, 2017. The settlement trust

administrator denied Schlager benefits, and Schlager contested that outcome.

Consistent with the terms of the class action settlement agreement, the District

Court then referred the dispute to arbitration. The arbitrator upheld the denial of benefits

related to Schlager’s 2010 surgery because the Green Form was submitted too late. Her

2017 Green Form was received over four years past both the entry of Court Approved

Procedure 16 and her 2010 surgery. The arbitrator also upheld the denial of benefits

related to Schlager’s 2014 stroke for two reasons: her stroke occurred after December 31,

2011, and she was 81 years old at the time.

Schlager then appealed the arbitrator’s decision to the District Court, which, in

exercising jurisdiction, see 28 U.S.C. § 1332, affirmed the arbitrator’s award.

Schlager appealed again to this Court. With jurisdiction over a final order

affirming an arbitration award, see 28 U.S.C. § 1291, we review factual findings for clear

error and legal conclusions de novo. See Sutter v. Oxford Health Plans LLC, 675 F.3d

215, 219 (3d Cir. 2012).

3 I

This appeal is not the first time that this Court has addressed an untimely claim by

Schlager to recover for her 2010 surgery. In 2015, she submitted two Green Forms

requesting Level III high-level matrix benefits based on that surgery. See generally In re

Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liab. Litig.,

763 F. App’x 237 (3d Cir. 2019). This Court determined that those Green Forms were

late and that their untimeliness could not be excused based on due process, lack of notice,

equitable tolling, or other reasons. Id. at 241-43, 243 n.25.

This time, Schlager seeks to recover based on a more untimely Green Form, which

sought greater benefits – those under Level IV, up from Level III. Schlager argues that

the 2017 Green Form should be deemed timely due to the discovery rule, the relation-

back doctrine, equitable tolling, class action protocols, and guidance from the Federal

Judicial Center. To put it mildly, none of those arguments have any merit.

Schlager first attempts to invoke discovery rule, by asserting that the deadlines

imposed by Court Approved Procedure 16 “worked a fraud on [her].” That argument

misapprehends the discovery rule at a fundamental level. The discovery rule tolls a

statute of limitations in certain instances based on the new discovery of an injury and its

cause – not for the discovery of a court-approved procedure for submitting claims. See

Schmidt v. Skolas, 770 F.3d 241, 251 (3d Cir. 2014); Crouse v. Cyclops Indus., 745 A.2d

606, 611 (Pa. 2000); see also Rotkiske v. Klemm, 140 S. Ct. 355, 361 (2019).

Schlager next argues that the relation-back doctrine should be applied to her 2017

Green Form. Specifically, she argues that the 2017 Green Form should relate back to her

4 2015 Green Forms. The relation-back doctrine is a rule of pleading, see Krupski v. Costa

Crociere S. p. A., 560 U.S. 538, 547 (2010), and it does not apply to claim forms

submitted to a settlement trust. Nor would relation-back preserve Schlager’s claims. As

this Court previously held, even those 2015 Green Forms were untimely. See In re Diet

Drugs, 763 F. App’x at 243.

Schlager’s equitable tolling arguments also come up empty. None of the

circumstances necessary for equitable tolling are present here. See In re Cmty. Bank of N.

Va. Mortg. Lending Practices Litig., 795 F.3d 380, 400 (3d Cir. 2015) (setting forth three

circumstances in which equitable tolling has been permitted). Nothing indicates that

Schlager was actively misled, that she was prevented from filing a Green Form, or that

she filed a Green Form in the wrong forum. See id.

In next arguing that she acted with “extraordinary diligence” in pursuing a claim

Free access — add to your briefcase to read the full text and ask questions with AI

Related

KRUPSKI v. COSTA CROCIERE S. P. A
560 U.S. 538 (Supreme Court, 2010)
John Sutter v. Oxford Health Plans
675 F.3d 215 (Third Circuit, 2012)
Crouse v. Cyclops Industries
745 A.2d 606 (Supreme Court of Pennsylvania, 2000)
Alan Schmidt v. John Skolas
770 F.3d 241 (Third Circuit, 2014)
Rotkiske v. Klemm
589 U.S. 8 (Supreme Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
In re: Diet Drugs v., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-diet-drugs-v-ca3-2020.